The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 05, 2023

Filed:

Apr. 07, 2021
Applicants:

Korea Basic Science Institute, Daejeon, KR;

University of Louisville Research Foundation, Inc., Louisville, KY (US);

Max-planck-gesellschaft Zur Foerderung Der Wissenschaften E.v., Munich, DE;

Inventors:

Kyoung-Seok Ryu, Daegu, KR;

Myeongkyu Kim, Gottingen, DE;

Christian Griesinger, Louisville, KY (US);

Donghan Lee, Louisville, KY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 31/655 (2006.01); A61K 38/12 (2006.01); A61K 31/4245 (2006.01); A61K 31/426 (2006.01); A61K 31/4196 (2006.01); A61K 31/506 (2006.01); A61K 31/404 (2006.01); A61K 31/343 (2006.01); A61K 31/4184 (2006.01); A61K 31/55 (2006.01); A61K 31/4709 (2006.01); A61K 31/4422 (2006.01); A61K 31/4725 (2006.01); A61K 31/196 (2006.01); A61K 31/4402 (2006.01); A61K 31/4418 (2006.01); A61K 31/41 (2006.01);
U.S. Cl.
CPC ...
A61K 31/655 (2013.01); A61K 31/196 (2013.01); A61K 31/343 (2013.01); A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/4184 (2013.01); A61K 31/4196 (2013.01); A61K 31/426 (2013.01); A61K 31/4245 (2013.01); A61K 31/4402 (2013.01); A61K 31/4418 (2013.01); A61K 31/4422 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/506 (2013.01); A61K 31/55 (2013.01); A61K 38/12 (2013.01);
Abstract

Method of increasing platelet counts in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound that inhibits Biliverdin reductase B (BLVRB) activity by blocking a binding site of BLVRB or a pharmaceutically acceptable salt thereof, wherein the compound does not contain xanthene or acridine moiety is provided.


Find Patent Forward Citations

Loading…